PMID: 2185150May 1, 1990Paper

Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X

P C WongP B Timmermans


In conscious 18-21-week-old spontaneously hypertensive rats, DuP 753, a nonpeptide angiotensin II receptor antagonist, given orally at 3 and 10 mg/kg or intravenously at 3, 10, and 30 mg/kg, reduced blood pressure dose dependently. It did not alter heart rate at these doses. At 10 mg/kg i.v., DuP 753 decreased blood pressure significantly for at least 24 hours, suggesting a long duration of the antihypertensive effect. Unlike saralasin, DuP 753 did not cause a transient increase in blood pressure. The acute antihypertensive efficacy of DuP 753 was greater than that of captopril. Our data indicate that, for captopril to reduce blood pressure to a similar extent as that of DuP 753, it would need to be supplemented by a diuretic. DuP 753 did not have an acute diuretic effect. Bilateral nephrectomy, but not inhibition of prostaglandin synthesis, abolished the antihypertensive effect of DuP 753, suggesting that the antihypertensive effect of DuP 753 is dependent on an active renin-angiotensin system. Furthermore, DuP 753 inhibited the pressor response to angiotensin II but not the responses to norepinephrine, vasopressin, and Bay K 8644 (a calcium agonist). As neither DuP 753 nor captopril decreased blood pressure acutely in Wistar-...Continue Reading


Apr 30, 1979·Pflügers Archiv : European journal of physiology·J SchnermannP C Weber
May 1, 1989·Hypertension·P C WongP B Timmermans
Jan 1, 1987·The Journal of Clinical Investigation·D J Campbell
Sep 1, 1987·The Medical Clinics of North America·M H Weinberger
Nov 15, 1988·European Journal of Pharmacology·A T ChiuP B Timmermans

❮ Previous
Next ❯


Nov 1, 1993·Journal of Clinical Pharmacology·R T EberhardtW H Frishman
Dec 1, 1995·Cellular and Molecular Neurobiology·J F Riordan
Jul 31, 2009·Archives of Pharmacal Research·Jae-Hong ChoiYun-Bae Kim
Sep 24, 1991·European Journal of Pharmacology·P C WongP B Timmermans
May 14, 1992·European Journal of Pharmacology·K MizunoS Fukuchi
Jun 23, 1994·European Journal of Pharmacology·R Radhakrishnan, M K Sim
Dec 29, 1995·European Journal of Pharmacology·S D KivlighnP K Siegl
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·J W Wright, J W Harding
Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
Apr 1, 1993·Journal of Pharmacological and Toxicological Methods·S H Chiu
Jun 5, 2003·Archives of Biochemistry and Biophysics·Per SvenssonPeter Westhoff
Nov 22, 1997·European Journal of Pharmacology·M ShibasakiI Yanagisawa
Apr 5, 2003·The International Journal of Biochemistry & Cell Biology·Christiane PeesPeter Gohlke
Sep 6, 2000·Clinical and Experimental Pharmacology & Physiology·J M BonnetJ Sassard
Aug 1, 1996·Journal of Cardiovascular Pharmacology·J D Symons, C L Stebbins
Dec 5, 1997·Journal of Cardiovascular Pharmacology·K TamuraK Hashimoto
Jun 26, 1998·Journal of Cardiovascular Pharmacology·C K KostE K Jackson
Feb 1, 1994·Clinical and Experimental Pharmacology & Physiology·Y Zhang, T Morgan
Jan 1, 1995·Clinical and Experimental Pharmacology & Physiology. Supplement·J NaguraF Konno
May 1, 1996·Clinical and Experimental Pharmacology & Physiology·C Y ChaiC J Tseng
Jan 1, 1995·Fundamental & Clinical Pharmacology·E GaudetJ L Elghozi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.